CLINICAL TRIALS PROFILE FOR IXINITY

All Clinical Trials for IXINITY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03855280 ↗	Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B	Active, not recruiting	Aptevo Therapeutics	Phase 3	2020-01-16	Phase 3/4, single arm, open-label study to evaluate PK, safety, and efficacy of APVO101 prophylaxis in severe or moderately severe hemophilia B subjects < 12 years of age.
NCT03855280 ↗	Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B	Active, not recruiting	Medexus Pharma, Inc.	Phase 3	2020-01-16	Phase 3/4, single arm, open-label study to evaluate PK, safety, and efficacy of APVO101 prophylaxis in severe or moderately severe hemophilia B subjects < 12 years of age.

Clinical Trial Conditions for IXINITY

Condition Name

Condition Name for IXINITY
Intervention	Trials
Hemophilia B	1

Condition MeSH

Condition MeSH for IXINITY
Intervention	Trials
Hemophilia B	1
Hemophilia A	1

Clinical Trial Locations for IXINITY

Trials by Country

Trials by Country for IXINITY
Location	Trials
Brazil	2
South Africa	2
Moldova, Republic of	1
Ukraine	1
Georgia	1

Clinical Trial Progress for IXINITY

Clinical Trial Phase

Clinical Trial Phase for IXINITY
Clinical Trial Phase	Trials
Phase 3	1

Clinical Trial Status

Clinical Trial Status for IXINITY
Clinical Trial Phase	Trials
Active, not recruiting	1

Clinical Trial Sponsors for IXINITY

Sponsor Name

Sponsor Name for IXINITY
Sponsor	Trials
Medexus Pharma, Inc.	1
Aptevo Therapeutics	1

Sponsor Type

Sponsor Type for IXINITY
Sponsor	Trials
Industry	2